{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:42:06Z","timestamp":1790635326427,"version":"4.1.0"},"reference-count":28,"publisher":"Walter de Gruyter GmbH","issue":"5","license":[{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_jpem-2023-0543_abs_001\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To understand possible predictors of the onset of menses after gonadotropin-releasing hormone agonist treatment cessation in girls with central precocious puberty (CPP).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2023-0543_abs_002\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This exploratory post hoc analysis of a phase 3 and 4 trial of girls with CPP treated with once-monthly intramuscular leuprolide acetate examined onset of menses after treatment completion using a time-to-event analysis. Pretreatment and end-of-treatment chronologic age (CA), bone age (BA)\/CA ratio, and Tanner breast stage; pretreatment menses status; and end-of-treatment BA and body mass index (BMI) were studied as potential factors influencing the onset of menses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2023-0543_abs_003\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Median time to first menses after stopping treatment was 18.3\u00a0months among 35 girls (mean age at onset of treatment, 6.8 years) examined. Of 26 girls experiencing menses, 11 (42\u202f%) menstruated at 16\u201321\u00a0months after stopping treatment. Most girls with pretreatment BA\/CA\u22651.4 started menstruating very close to 18\u00a0months after stopping treatment; those with less advanced BA\/CA experienced menses at 9\u201318\u00a0months. End-of-treatment BA\/CA\u22651.2 was associated with a quicker onset of menses (14.5 vs. 18.5\u00a0months for BA\/CA&lt;1.2, p=0.006). End-of-treatment BA\u226512 years predicted longer time to menses. No relationship with time to menses was observed for pretreatment menarche status, pretreatment or end-of-treatment Tanner breast stage (&lt;3\/\u22653) or CA (&lt;6\/\u22656 or\u00a0\u226411\/&gt;11), or end-of-treatment BMI percentiles (&lt;85.6\/\u226585.6 and &lt;92.6\/\u226592.6).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2023-0543_abs_004\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Pretreatment menarche status or CA do not appear to predict onset of menses, but pre- and end-of-treatment BA\/CA may be helpful in anticipating time to first menses after stopping treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/jpem-2023-0543","type":"journal-article","created":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T09:10:37Z","timestamp":1713172237000},"page":"451-461","source":"Crossref","is-referenced-by-count":7,"title":["Timing of onset of menses after GnRH agonist treatment for central precocious puberty"],"prefix":"10.1515","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7953-4691","authenticated-orcid":false,"given":"Karen O.","family":"Klein","sequence":"first","affiliation":[{"name":"Rady Children\u2019s Hospital , San Diego , CA , USA"},{"name":"Department of Pediatrics , University of California , San Diego , CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela","family":"Vargas Trujillo","sequence":"additional","affiliation":[{"name":"Rady Children\u2019s Hospital , San Diego , CA , USA"},{"name":"Department of Pediatrics , University of California , San Diego , CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Dragnic","sequence":"additional","affiliation":[{"name":"AbbVie , North Chicago , IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Van Komen","sequence":"additional","affiliation":[{"name":"AbbVie , North Chicago , IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moming","family":"Li","sequence":"additional","affiliation":[{"name":"AbbVie , North Chicago , IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics , Penn State Hershey Medical Center , Hershey , PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2024,4,15]]},"reference":[{"key":"2024081908520413066_j_jpem-2023-0543_ref_001","doi-asserted-by":"crossref","unstructured":"Aguirre, RS, Eugster, EA. Central precocious puberty: from genetics to treatment. Best Pract Res Clin Endocrinol Metabol 2018;32:343\u201354. https:\/\/doi.org\/10.1016\/j.beem.2018.05.008.","DOI":"10.1016\/j.beem.2018.05.008"},{"key":"2024081908520413066_j_jpem-2023-0543_ref_002","doi-asserted-by":"crossref","unstructured":"Chen, M, Eugster, EA. Central precocious puberty: update on diagnosis and treatment. Paediatr Drugs 2015;17:273\u201381. https:\/\/doi.org\/10.1007\/s40272-015-0130-8.","DOI":"10.1007\/s40272-015-0130-8"},{"key":"2024081908520413066_j_jpem-2023-0543_ref_003","doi-asserted-by":"crossref","unstructured":"Eugster, EA. Treatment of central precocious puberty. J Endocr Soc 2019;3:965\u201372. https:\/\/doi.org\/10.1210\/js.2019-00036.","DOI":"10.1210\/js.2019-00036"},{"key":"2024081908520413066_j_jpem-2023-0543_ref_004","doi-asserted-by":"crossref","unstructured":"Kaplowitz, P, Bloch, C, Sills, IN, Casella, SJ, Gonzalez, JL, Lynch, JL, et al.. Section on endocrinology, American Academy of Pediatrics. Evaluation and referral of children with signs of early puberty. Pediatrics 2016;137:e20153732. https:\/\/doi.org\/10.1542\/peds.2015-3732.","DOI":"10.1542\/peds.2015-3732"},{"key":"2024081908520413066_j_jpem-2023-0543_ref_005","doi-asserted-by":"crossref","unstructured":"Bangalore Krishna, K, Fuqua, JS, Rogol, AD, Klein, KO, Popovic, J, Houk, CP, et al.. Use of gonadotropin-releasing hormone analogs in children: update by an international consortium. Horm Res Paediatr 2019;91:357\u201372. https:\/\/doi.org\/10.1159\/000501336.","DOI":"10.1159\/000501336"},{"key":"2024081908520413066_j_jpem-2023-0543_ref_006","doi-asserted-by":"crossref","unstructured":"Carel, JC, Eugster, EA, Rogol, A, Ghizzoni, L, Palmert, MR, Espe-Lwpes GnRH Analogs Consensus Conference Group. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 2009;123:e752\u201362. https:\/\/doi.org\/10.1542\/peds.2008-1783.","DOI":"10.1542\/peds.2008-1783"},{"key":"2024081908520413066_j_jpem-2023-0543_ref_007","doi-asserted-by":"crossref","unstructured":"Fuqua, JS. Treatment and outcomes of precocious puberty: an update. J Clin Endocrinol Metab 2013;98:2198\u2013207. https:\/\/doi.org\/10.1210\/jc.2013-1024.","DOI":"10.1210\/jc.2013-1024"},{"key":"2024081908520413066_j_jpem-2023-0543_ref_008","doi-asserted-by":"crossref","unstructured":"Knific, T, Lazarevi\u010d, M, \u017dibert, J, Obolnar, N, Aleksovska, N, \u0160uput Omladi\u010d, J, et al.. Final adult height in children with central precocious puberty\u00a0\u2013 a retrospective study. Front Endocrinol 2022;13:1008474. https:\/\/doi.org\/10.3389\/fendo.2022.1008474.","DOI":"10.3389\/fendo.2022.1008474"},{"key":"2024081908520413066_j_jpem-2023-0543_ref_009","doi-asserted-by":"crossref","unstructured":"Kaplowitz, PB, Backeljauw, PF, Allen, DB. Toward more targeted and cost-effective gonadotropin-releasing hormone analog treatment in girls with central precocious puberty. Horm Res Paediatr 2018;90:1\u20137. https:\/\/doi.org\/10.1159\/000491103.","DOI":"10.1159\/000491103"},{"key":"2024081908520413066_j_jpem-2023-0543_ref_010","doi-asserted-by":"crossref","unstructured":"Mul, D, Oostdijk, W, Otten, BJ, Rouwe, C, Jansen, M, Delemarre-van de Waal, HA, et al.. Final height after gonadotrophin releasing hormone agonist treatment for central precocious puberty: the Dutch experience. J Pediatr Endocrinol Metab 2000;13(1 suppl):765\u201372. https:\/\/doi.org\/10.1515\/jpem.2000.13.s1.765.","DOI":"10.1515\/JPEM.2000.13.S1.765"},{"key":"2024081908520413066_j_jpem-2023-0543_ref_011","doi-asserted-by":"crossref","unstructured":"Trujillo, MV, Dragnic, S, Aldridge, P, Klein, KO. Importance of individualizing treatment decisions in girls with central precocious puberty when initiating treatment after age 7 years or continuing beyond a chronological age of 10 years or a bone age of 12 years. J Pediatr Endocrinol Metab 2021;34:733\u20139. https:\/\/doi.org\/10.1515\/jpem-2021-0114.","DOI":"10.1515\/jpem-2021-0114"},{"key":"2024081908520413066_j_jpem-2023-0543_ref_012","doi-asserted-by":"crossref","unstructured":"Trujillo, MV, Lee, PA, Reifschneider, K, Backeljauw, PF, Dragnic, S, Van Komen, S, et al.. Using change in predicted adult height during GnRH agonist treatment for individualized treatment decisions in girls with central precocious puberty. J Pediatr Endocrinol Metab 2023;36:299\u2013308. https:\/\/doi.org\/10.1515\/jpem-2022-0476.","DOI":"10.1515\/jpem-2022-0476"},{"key":"2024081908520413066_j_jpem-2023-0543_ref_013","doi-asserted-by":"crossref","unstructured":"Baek, JW, Nam, HK, Jin, D, Oh, YJ, Rhie, YJ, Lee, KH. Age of menarche and near adult height after long-term gonadotropin-releasing hormone agonist treatment in girls with central precocious puberty. Ann Pediatr Endocrinol Metab 2014;19:27\u201331. https:\/\/doi.org\/10.6065\/apem.2014.19.1.27.","DOI":"10.6065\/apem.2014.19.1.27"},{"key":"2024081908520413066_j_jpem-2023-0543_ref_014","doi-asserted-by":"crossref","unstructured":"Briscoe, A, Chen, K, Klein, KO. No pubertal growth spurt, rapid bone maturation, and menarche post GnRHa treatment in girls with precocious puberty. J Pediatr Endocrinol Metab 2022;35:1401\u20139. https:\/\/doi.org\/10.1515\/jpem-2022-0389.","DOI":"10.1515\/jpem-2022-0389"},{"key":"2024081908520413066_j_jpem-2023-0543_ref_015","doi-asserted-by":"crossref","unstructured":"Fisher, MM, Lemay, D, Eugster, EA. Resumption of puberty in girls and boys following removal of the histrelin implant. J Pediatr 2014;164:912\u20136.e1. https:\/\/doi.org\/10.1016\/j.jpeds.2013.12.009.","DOI":"10.1016\/j.jpeds.2013.12.009"},{"key":"2024081908520413066_j_jpem-2023-0543_ref_016","doi-asserted-by":"crossref","unstructured":"Gillis, D, Karavani, G, Hirsch, HJ, Strich, D. Time to menarche and final height after histrelin implant treatment for central precocious puberty. J Pediatr 2013;163:532\u20136. https:\/\/doi.org\/10.1016\/j.jpeds.2013.01.021.","DOI":"10.1016\/j.jpeds.2013.01.021"},{"key":"2024081908520413066_j_jpem-2023-0543_ref_017","doi-asserted-by":"crossref","unstructured":"Gyon, Y, Yun, YJ, Kim, YD, Han, HS. Age at menarche and near final height after treatment with gonadotropin-releasing hormone agonist alone or combined with growth hormone in Korean girls with central precocious puberty. Clin Pediatr Endocrinol 2015;24:175\u201383. https:\/\/doi.org\/10.1297\/cpe.24.175.","DOI":"10.1297\/cpe.24.175"},{"key":"2024081908520413066_j_jpem-2023-0543_ref_018","doi-asserted-by":"crossref","unstructured":"Jay, N, Mansfield, MJ, Blizzard, RM, Crowley, WFJr., Schoenfeld, D, Rhubin, L, et al.. Ovulation and menstrual function of adolescent girls with central precocious puberty after therapy with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 1992;75:890\u20134. https:\/\/doi.org\/10.1210\/jcem.75.3.1517382.","DOI":"10.1210\/jcem.75.3.1517382"},{"key":"2024081908520413066_j_jpem-2023-0543_ref_019","doi-asserted-by":"crossref","unstructured":"Kim, EY. Long-term effects of gonadotropin-releasing hormone analogs in girls with central precocious puberty. Korean J Pediatr 2015;58:1\u20137. https:\/\/doi.org\/10.3345\/kjp.2015.58.1.1.","DOI":"10.3345\/kjp.2015.58.1.1"},{"key":"2024081908520413066_j_jpem-2023-0543_ref_020","doi-asserted-by":"crossref","unstructured":"Lee, PA, Neely, EK, Fuqua, J, Yang, D, Larsen, LM, Mattia-Goldberg, C, et al.. Efficacy of leuprolide acetate 1\u00a0month depot for central precocious puberty (CPP): growth outcomes during a prospective, longitudinal study. Int J Pediatr Endocrinol 2011;2011:7. https:\/\/doi.org\/10.1186\/1687-9856-2011-7.","DOI":"10.1186\/1687-9856-2011-7"},{"key":"2024081908520413066_j_jpem-2023-0543_ref_021","doi-asserted-by":"crossref","unstructured":"Neely, EK, Lee, PA, Bloch, CA, Larsen, L, Yang, D, Mattia-Goldberg, C, et al.. Leuprolide acetate 1\u00a0month depot for central precocious puberty: hormonal suppression and recovery. Int J Pediatr Endocrinol 2010;2010:398639. https:\/\/doi.org\/10.1155\/2010\/398639.","DOI":"10.1186\/1687-9856-2010-398639"},{"key":"2024081908520413066_j_jpem-2023-0543_ref_022","doi-asserted-by":"crossref","unstructured":"Oostdijk, W, Rikken, B, Schreuder, S, Otten, B, Odink, R, Rouwe, C, et al.. Final height in central precocious puberty after long term treatment with a slow release GnRH agonist. Arch Dis Child 1996;75:292\u20137. https:\/\/doi.org\/10.1136\/adc.75.4.292.","DOI":"10.1136\/adc.75.4.292"},{"key":"2024081908520413066_j_jpem-2023-0543_ref_023","doi-asserted-by":"crossref","unstructured":"Paterson, WF, McNeill, E, Young, D, Donaldson, MD. Auxological outcome and time to menarche following long-acting goserelin therapy in girls with central precocious or early puberty. Clin Endocrinol 2004;61:626\u201334. https:\/\/doi.org\/10.1111\/j.1365-2265.2004.02146.x.","DOI":"10.1111\/j.1365-2265.2004.02146.x"},{"key":"2024081908520413066_j_jpem-2023-0543_ref_024","doi-asserted-by":"crossref","unstructured":"Poomthavorn, P, Suphasit, R, Mahachoklertwattana, P. Adult height, body mass index and time of menarche of girls with idiopathic central precocious puberty after gonadotropin-releasing hormone analogue treatment. Gynecol Endocrinol 2011;27:524\u20138. https:\/\/doi.org\/10.3109\/09513590.2010.507289.","DOI":"10.3109\/09513590.2010.507289"},{"key":"2024081908520413066_j_jpem-2023-0543_ref_025","doi-asserted-by":"crossref","unstructured":"Wu, V, Zhao, V, Issa, R, Wilkes, M, Wallach, E, Rapaport, R, et al.. Clinical findings influencing time to menarche post gonadotropin-releasing hormone agonist therapy in central precocious puberty. Ann Pediatr Endocrinol Metab 2021;26:185\u201391. https:\/\/doi.org\/10.6065\/apem.2040220.110.","DOI":"10.6065\/apem.2040220.110"},{"key":"2024081908520413066_j_jpem-2023-0543_ref_026","unstructured":"AbbVie Inc. LUPRON DEPOT-PED\u00ae (leuprolide acetate for depot suspension). Full prescribing information. North Chicago, IL: AbbVie, Inc.; 2022."},{"key":"2024081908520413066_j_jpem-2023-0543_ref_027","unstructured":"Roche, AF, Chumlea, WC, Thissen, D. Assessing the skeletal maturity of the hand-wrist: FELS method. Springfield, IL: Charles C Thomas Pub Ltd; 1988."},{"key":"2024081908520413066_j_jpem-2023-0543_ref_028","doi-asserted-by":"crossref","unstructured":"Magiakou, MA, Manousaki, D, Papadaki, M, Hadjidakis, D, Levidou, G, Vakaki, M, et al.. The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: a single center, long-term follow-up study. J Clin Endocrinol Metab 2010;95:109\u201317. https:\/\/doi.org\/10.1210\/jc.2009-0793.","DOI":"10.1210\/jc.2009-0793"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2023-0543\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2023-0543\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T08:52:24Z","timestamp":1724057544000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2023-0543\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,15]]},"references-count":28,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,3,7]]},"published-print":{"date-parts":[[2024,5,27]]}},"alternative-id":["10.1515\/jpem-2023-0543"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2023-0543","relation":{},"ISSN":["0334-018X","2191-0251"],"issn-type":[{"value":"0334-018X","type":"print"},{"value":"2191-0251","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,15]]}}}